For example, mutations in the EGFR protein kinase domain are found in 10–30% of lung adenocarcinomas, and treatment with tyrosine kinase inhibitors that specifically target the mutant protein kinase can produce temporary remissions in lung cancer patients4. Here, EGFR is linked to lung carcinoma.